Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.
Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson’s disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has...
US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to merge with Keryx Biopharmaceuticals appeared first on Pharmaceutical Technology.
A round of Series A financing has been closed by Aurora, Colo.-based Cerebral Therapeutics at $3 million. -More-
Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technologyPatent covers use of optimized guide RNA molecules ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences,...
SQZ Therapeutics is working on a new way to get medicines into cells — and it's had a very busy fall.
Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven Therapeutics, POXEL, Ossianix appeared first on Drug Development Technology.
Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics
Shares of Axsome Therapeutics Inc. (AXSM) have returned 15% so far this month while the iShares Nasdaq Biotechnology ETF (IBB) has gained just 3% for the same period.
CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte’s cell engineering platform. The partnership is an...Read More... The post Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences appeared first on Drug Development Technology.
Neon Therapeutics Inc. (immuno-oncology) filed for its initial public offering.
United Therapeutics has agreed to license and co-develop MannKind’s clinical-phase dry powder formulation of the pulmonary arterial hypertension (PAH) treatment treprostinil—the active ingredient in United Therapeutics’ top-selling drugs Remodulin® and Tyvaso®—through a collaboration that could generate more than $95 million for MannKind, the companies said today. Under their...
Drug makers are making more bets on the nascent field of digital medicine. The latest example: Click Therapeutics announced Monday that it grabbed a $17 million investment led by Sanofi Ventures, the Cambridge, MA-based venture capital arm of the French pharmaceutical giant. New York-based Click Therapeutics develops mobile apps intended to be prescribed by doctors […]
US-based biopharmaceutical company MannKind has entered an exclusive licensing and collaboration agreement with United Therapeutics over a dry powder formulation...Read More... The post MannKind and United Therapeutics to advance dry powder treprostinil appeared first on Pharmaceutical Technology.
Newsoara will develop vTv Therapeutics' HPP737 as a new treatment for chronic obstructive pulmonary disease
Shares of Checkpoint Therapeutics Inc. (CKPT), a majority controlled subsidiary of Fortress Biotech Inc. (FBIO), are well off their highs recorded last September, and trade around $3.
United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.
LNC Therapeutics licensed exclusive rights to Christensenella patents from Cornell University.
Briacell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) CEO William Williams speaks with Proactive Investor's Christine Corrado at the MicroCap Conference in New York. BriaCell Therapeutics Corp. is an immuno-oncology company which develops immunotherapy treatments for cancer. BriaCell is currently focused on the clinical development of Bria-IMT™ as a 2nd line treatment for patients with adva...
Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was &po...
Nestlé Health Science has raised its equity stake in biopharmaceutical firm Aimmune Therapeutics to around 19% with an investment of...Read More... The post Nestle Health increases stake in Aimmune Therapeutics appeared first on Pharmaceutical Technology.
MALVERN, Pa., Nov. 29, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized Read more...
United Therapeutics' PrUnituxin, or dinutuximab, in combination with granulocyte-macrophage colony-stimulating factor, interl -More-
TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.
A Series A funding round brought in about $15.7 million for Swedish biotech Modus Therapeutics, which the company will use to -More-